药物流行病学在临床药物评价中的应用

李旭晗,冼静怡,杨燕,李慧杰,范正悦,宋晶,杨佳,宗晓郁,吕旋瑞,王萌萌,柴栋,宫建

Application of Pharmacoepidemiology in Clinical Drug Evaluation

Xuhan LI,Jingyi XIAN,Yan YANG,Huijie LI,Zhengyue FAN,Jing SONG,Jia YANG,Xiaoyu ZONG,Xuanrui LYU,Mengmeng WANG,Dong CHAI,Jian GONG

图2 他汀类药物干预策略的马尔可夫模型 P1:从未患心血管病状态到患有心血管病状态的概率;P2:从未患心血管病状态到死于心血管病状态的概率;P3:从未患心血管病状态到死于其他疾病状态的概率;P4:未患心血管病存活状态的概率;P5:从患有心血管病状态到死于心血管病状态的概率;P6:从患有心血管病状态到死于其他疾病状态的概率;P7:患有心血管病存活状态的概率。

Fig.2 Markov model of statin intervention strategy P1:Probability of never having a cardiovascular disease state to having a cardiovascular disease state;P2:Probability of never having a cardiovascular disease state to dying from a cardiovascular disease state;P3:Probability of never having a cardiovascular disease state to dying from other disease states;P4:Probability of survival without cardiovascular disease;P5:Probability of having a cardiovascular disease state to dying from cardiovascular disease status;P6:Probability of having a cardiovascular disease state to dying from other disease states;P7:Probability of survival from cardiovascular disease.